4SC has significantly expanded the patent protection for 4SC-202, its second epigenetic anticancer compound, in Japan and other attractive Asian growth markets. The oral agent modulates the cellular Wnt signalling pathway that plays a key role in cancer development and growth. It is currently being investigated in a Phase I trial in patients with haematological tumours.
In Japan and South Korea, 4SC has now received Notice of Allowance from the patent authorities, making the granting of the composition-of-matter patent for 4SC-202 imminent. In India, the composition-of-matter patent has already been granted (Patent No. 252846). The patents cover the composition of matter of the 4SC-202 compound itself, the pharmaceutical compositions containing the compound, and the therapeutic use of 4SC-202 in the treatment of cancer and in other therapy areas.